Crossmark

Rationale for the Use of Fixed Combination Therapies with Angiotensin Converting Enzyme Inhibitors and Beta-Blockers in Patients with Essential Hypertension and High Cardiovascular Risk: A Consensus Document from the Italian Society of Arterial Hypertension (Siia) and the Italian Society of Cardiovascular Prevention (SIPREC)

Crossref DOI link: https://doi.org/10.1007/s40292-025-00761-6

Published Online: 2025-11-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Virdis, Agostino https://orcid.org/0000-0002-6994-0223
Tocci, Giuliano https://orcid.org/0000-0002-0635-4921
Muiesan, Maria Lorenza https://orcid.org/0000-0002-4007-9441
Desideri, GiovamBattista https://orcid.org/0000-0002-0145-1271
Viazzi, Francesca https://orcid.org/0000-0003-4219-7043
Albini, Fabio Lucio https://orcid.org/0000-0003-3388-7667
Sarzani, Riccardo https://orcid.org/0000-0002-5159-0181
Giovanna, Gallo https://orcid.org/0000-0003-4845-117X
Grassi, Guido https://orcid.org/0000-0003-1922-6547
Volpe, Massimo https://orcid.org/0000-0002-9642-8380
License Information

Text and Data Mining valid from 2025-11-21

Version of Record valid from 2025-11-21
More Information

Article History

Received: 28 August 2025

Accepted: 30 October 2025

First Online: 21 November 2025

Change Date: 21 January 2026

Change Type: Update

Change Details: The original online version of this article was revised for funding note added.

Declarations

:

: The present manuscript was partially supported by unrestricted research grant provided by Sandoz Italia S.p.A. to the Italian Society of Arterial Hypertension (SIIA) and the Italian Society of Cardiovascular Prevention (SIPREC).

: Not applicable for the contents of the present consensus document.

Document is current

Any future updates will be listed below